Press Release

<< Back
View printer-friendly version

Spark Therapeutics, Inc. to Host Conference Call on May 6th at 8:30a.m. to Discuss First Quarter 2015 Results

PHILADELPHIA, April 30, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (Nasdaq:ONCE) today announced that it will host a conference call on Wednesday, May 6, 2015 at 8:30 a.m. Eastern to report corporate and financial results for the three months ended March 31, 2015.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 37192364. To access a live audio webcast, please visit the "Investors" section at www.sparktx.com.

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 37192364 or also available on our website.

About Spark Therapeutics

Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Spark's initial focus is on treating orphan diseases where no, or only palliative, therapies exist. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully enrolled pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark is leveraging the experience and technology utilized in the development of SPK-RPE65 to address a broad spectrum of blinding conditions, starting with the development of SPK-CHM for the potential treatment of choroideremia, currently in a Phase 1/2 clinical trial. Spark also is establishing a pipeline of gene therapy candidates to treat hematologic disorders and neurodegenerative diseases, including through a global collaboration with Pfizer Inc. around the development and commercialization of its SPK-FIX program for the treatment of hemophilia B. Spark's integrated gene therapy platform builds on two decades of research, development and manufacturing at The Children's Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.

CONTACT: Investor Relations
         Spark Therapeutics, Inc.Stephen W. Webster
         Chief Financial Officer
         (888) 772-7560

         or

         Media Contact
         Feinstein Kean HealthcareJessica Rowlands
         (202) 729-4089

Spark Therapeutics Logo

Spark Therapeutics